<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067169</url>
  </required_header>
  <id_info>
    <org_study_id>I09013 ORPHAVIC</org_study_id>
    <nct_id>NCT02067169</nct_id>
  </id_info>
  <brief_title>A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.</brief_title>
  <acronym>ORPHAVIC</acronym>
  <official_title>A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era. Survey of Pharmacological and Virological Resistance of Cytomegalovirus to Antiviral Therapy in Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resistance to antivirals is a growing problem in transplantation.that may concerns up to 5%
      of patients treated for cytomegalovirus (CMV) syndrome or disease in recent per-protocol
      studies. This prevalence vary with the organ transplanted and the degree of viral replication
      and immunosuppression. Less data are available to date from real-life cohorts of patients,
      and there is no systematic survey of resistance in Europe or in the US. Non response to
      treatment concerns a larger group of patients and can result either from emergence of a
      resistant strain (virological resistance), from inadequate dosage of antivirals, or a high
      degree of immunosuppression, with a poor CMV immune response. The respective clinical impact
      of virological resistance and clinical resistance (of pharmacological or immunological
      origin) on graft outcome and long-term survival of patients has never been assessed. High
      viral loads and persistent replication associated to prolonged exposure to antivirals are
      known to favor the emergence of resistant strains. Though epidemiology of resistant strains,
      role of multiple infections, impact of various mutations on degree of resistance to
      antivirals and outcome remains to be further studied. Most studies are per-protocol studies
      or short-term studies conducted on limited populations. There are no data in real-life of
      transplanted patients at the era of enlarged prophylaxis except those from the French survey
      for cytomegalovirus resistance cohort opened at the end of 2006. From the first data
      collected on 346 patients we shown a 10,6% prevalence of non-response to therapy with 5,2% of
      virological resistance (6,1% incidence at one year on 214 patients) with a trend to poorer
      outcome in case of virological resistance and to the absence of impact of prophylaxis versus
      preemptive therapy, though larger populations and prolonged follow-up are requested to
      fulfill all objectives.

      We therefore aim to constitute a prolonged survey cohort for CMV resistance with a large
      number of patients and a prolonged follow-up, to gather data on resistance to antivirals in
      real-life of transplant patients in an organized data bank, This cohort is in the continuum
      of our previous cohort started in 2006, granted by the Hospital Clinical Research Program
      Interregional (PHRC), with the same major objectives and prolonged follow-up of patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence and incidence of resistance of cytomegalovirus</measure>
    <time_frame>3 weeks</time_frame>
    <description>Non response to therapy is defined as persistent viral replication after more than 3 weeks of appropriate antiviral treatment, with or without clinical manifestations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacological and virological resistance</measure>
    <time_frame>2 years</time_frame>
    <description>Measure the respective incidence of pharmacological and virological resistance</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">408</enrollment>
  <condition>Transplant Recipients With CMV Infection</condition>
  <arm_group>
    <arm_group_label>CMV infection</arm_group_label>
    <description>allograft recipient with active CMV infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV Infection</intervention_name>
    <description>Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.</description>
    <arm_group_label>CMV infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Detection of the CMV in sang, the leukocytes, or plasma with or without the viral
      quantification and/or the sample of urine of saliva or tissues, positive for research of CMV.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        allograft recipient or hematopoietic stem cell or solid organ.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allograft recipient with active CMV infection,

          -  or patient from the previous cohort, without opposition to biological collection of
             samples

        Exclusion Criteria:

          -  not willing to participate, no health insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie ALAIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Limoges UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Amiens</city>
        <zip>80</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Angers</city>
        <zip>49</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Besancon</city>
        <zip>25</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Brest</city>
        <zip>29</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Caen</city>
        <zip>14</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Beaujon - Virologie</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital MONDOR - Virologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Dijon</city>
        <zip>21</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Lille</city>
        <zip>59</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bactériologie Virologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCLYON - Virologie - Hôpital La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69314</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Lyon</city>
        <zip>69</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie - AP-HM - La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nancy</city>
        <zip>54</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nantes</city>
        <zip>44</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nimes</city>
        <zip>30</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Saint-Antoine - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Georges Pompidou - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital TENON - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital BICHAT</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital NECKER</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital SAINT-LOUIS</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Reims</city>
        <zip>51</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Rennes</city>
        <zip>35</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Rouen</city>
        <zip>76</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Tours</city>
        <zip>37</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>CMV infection</keyword>
  <keyword>antiviral resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

